Orthocell Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
2,182.20
3,742.70
3,784.90
4,177.40
5,757.10
Depreciation, Depletion & Amortization
37.80
59.40
100.20
147.80
193.30
Other Funds
51.20
841.70
288.30
273.90
581.00
Funds from Operations
2,093.20
2,841.70
3,396.30
3,755.70
4,982.80
Changes in Working Capital
340.10
74.00
75.20
200.40
338.60
Net Operating Cash Flow
1,753.00
2,767.60
3,321.10
3,555.40
4,644.30
Capital Expenditures
273.30
319.30
328.30
363.50
373.60
Net Investing Cash Flow
273.30
319.30
328.30
363.50
373.60
Net Financing Cash Flow
4,902.50
4,393.70
4,057.10
3,783.30
2,881.80
Net Change in Cash
2,876.20
1,306.80
407.70
135.60
2,136.00
Free Cash Flow
1,757.90
2,823.70
3,362.10
3,663.30
4,731.40
Change in Capital Stock
4,902.50
4,393.70
4,057.10
3,783.30
2,881.80

About Orthocell

View Profile
Address
Building 191
Murdoch Western Australia (WA) 6150
Australia
Employees -
Website http://www.orthocell.com.au
Updated 07/08/2019
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. Its products include CelGro which derives collagen medical device for soft tissue repair; and Antologous Tenocyte Implantation (Ortho-ATI) for chronic, treatment resistant tendon injuries. The company was founded by Paul Anderson and Min Hao Zheng on March 21, 2006 and is headquartered in Murdoch, Australia.